

specification, e.g., at paragraph 0033. The amendments thus do not add any new matter to the application.

With regard to the Restriction Requirement set forth by the Examiner, Applicants point out that there is an apparent error in the Examiner's grouping of claims, namely with regard to the subject matter of claim 1, the antibody which can bind to the propeptide of the Int1p protein of *Candida albicans*. In particular, the Examiner's requirement sets forth that in group 5, Claims 1, 3, 4 and 9-11 are "drawn to an antibody against Int1p protein of *Candida albicans*", and the Examiner puts these claims into a separate group from Claim 2 (Group 1) drawn to the "antibody to the propeptide region at amino acids 1-263." This distinction apparently resulted from an oversight by the Examiner in that Claim 1 does not refer to an antibody "against the Int1p protein" as stated by the Examiner, but instead refers to an antibody to the propeptide region of Int1p protein which Applicants would like to elect as the subject matter of the present application.


Thus, Applicants wish to elect the subject matter of the claims directed to an antibody to the propeptide of the *C. albicans* Int1p protein, and Applicants submit that these claims properly include Claim 1, Claim 2, Claim 3, Claim 4, Claims 9-11, Claim 13 and Claim 23, and as the Examiner recognized, these claims should be linked with Claims 12, 14, 15 and 17.

To the extent necessary to complete the response despite the obvious error of the Examiner with regard to inadvertently placing Claim 1 in a separate group from Claim 2, Applicants will provisionally elect, only for purposes of this response, the Group designated as Group 1 in the Restriction Response of January 3, 2003.

Should the Examiner wish to discuss the above response in an effort to expedite prosecution of this application, a telephone call to the undersigned is welcomed.

In light of the foregoing, Applicants hereby request examination of the claims directed to the antibody to the propeptide of the *C. albicans* Int1p protein, and examination and allowance of the application is thus respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'B. Aaron Schulman', is written over a horizontal line.

B. Aaron Schulman  
Registration No. 31,877

January 29, 2003

LARSON & TAYLOR, PLC  
1199 North Fairfax Street  
Suite 900  
Alexandria, Virginia 22314  
(703) 739-4900



## ATTACHMENT A

### Marked-Up Amended Claims

*The following are marked-up versions of the amended claims:*

1. An isolated antibody generated ~~against~~ that can bind to the propeptide of the Int1p protein of *Candida albicans*.

2. (An isolated antibody according to claim 1 wherein the propeptide has the sequence of amino acids 1-263 of the Int1p protein as shown in Fig. 1 of SEQ ID NO:1).

N-Terminal is Int1  
35 KDa  
(pep263)

Anti-Int1 600  
Fig 11

RECEIVED

JAN 31 2003

TECH CENTER 1800/2900